Compositions and methods for treating pulmonary edema or lung inflammation
AssigneeRegents of the University of Minnesota
InventorsDavid H. Ingbar, Timothy P. Rich, Robert J. Schumacher
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.
Claims11
A method of treating acute respiratory distress syndrome (ARDS) in a subject, the method comprising:
- measuring a first serum triiodothyronine (T3) level in the subject;
- determining the first serum T3 level to be below an established minimum value of a normal range for the assay used;
- providing an initial dose of T3 directly to the sinopulmonary tract of the subject;
- measuring a second serum T3 level after an initial interval of time;
- determining the second serum T3 level to be below the established maximum value of the normal range for the assay used;
- and
- providing a second dose of T3 to the subject that is greater than the first dose.
A method of treating acute respiratory distress syndrome (ARDS) in a subject, the method comprising:
- measuring a first serum triiodothyronine (T3) level in the subject;
- determining the first serum T3 level to be below an established minimum value of a normal range for the assay used;
- providing an initial dose of T3 directly to the sinopulmonary tract of the subject;
- measuring a second serum T3 level after an initial interval of time;
- determining the second serum T3 level to be at least the established minimum value of the normal range for the assay used;
- and
- providing a second dose of T3 to the subject that is the same dose as the first dose.
A method of treating acute respiratory distress syndrome (ARDS) in a subject, the method comprising:
- providing multiple doses of triiodothyronine (T3) directly to the sinopulmonary tract of the subject until serum level of T3 in the subject reaches an established minimum value of a normal range for the assay used;
- and
- providing one or more subsequent doses until the symptoms are ameliorated.
Dependencies are inferred from the claim text.